{"doi":"10.3390/ijms25179134","title":"Polθ Inhibitor (ART558) Demonstrates a Synthetic Lethal Effect with PARP and RAD52 Inhibitors in Glioblastoma Cells","abstract":"<jats:p>DNA repair proteins became the popular targets in research on cancer treatment. In our studies we hypothesized that inhibition of DNA polymerase theta (Polθ) and its combination with Poly (ADP-ribose) polymerase 1 (PARP1) or RAD52 inhibition and the alkylating drug temozolomide (TMZ) has an anticancer effect on glioblastoma cells (GBM21), whereas it has a low impact on normal human astrocytes (NHA). The effect of the compounds was assessed by analysis of cell viability, apoptosis, proliferation, DNA damage and cell cycle distribution, as well as gene expression. The main results show that Polθ inhibition causes a significant decrease in glioblastoma cell viability. It induces apoptosis, which is accompanied by a reduction in cell proliferation and DNA damage. Moreover, the effect was stronger when dual inhibition of Polθ with PARP1 or RAD52 was applied, and it is further enhanced by addition of TMZ. The impact on normal cells is much lower, especially when considering cell viability and DNA damage. In conclusion, we would like to highlight that Polθ inhibition used in combination with PARP1 or RAD52 inhibition has great potential to kill glioblastoma cells, and shows a synthetic lethal effect, while sparing normal astrocytes.</jats:p>","journal":"International Journal of Molecular Sciences","year":2024,"id":674952,"datarank":0.37273599746820013,"base_score":2.4849066497880004,"endowment":2.4849066497880004,"self_citation_contribution":0.37273599746820013,"citation_network_contribution":0.0,"self_endowment_contribution":0.37273599746820013,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":11,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1763526,"name":"Piotr Czarny","orcid":"0000-0002-5146-5225","position":1,"is_corresponding":false},{"id":1763528,"name":"Małgorzata Drzewiecka","orcid":"0000-0002-5869-7993","position":2,"is_corresponding":false},{"id":1763529,"name":"Maciej Błaszczyk","orcid":null,"position":3,"is_corresponding":false},{"id":1763531,"name":"Maciej Radek","orcid":"0000-0003-3544-1482","position":4,"is_corresponding":false},{"id":711068,"name":"Ewelina Synowiec","orcid":"0000-0002-0730-4491","position":5,"is_corresponding":false},{"id":1763532,"name":"Paulina Wigner-Jeziorska","orcid":null,"position":6,"is_corresponding":false},{"id":1763533,"name":"Przemysław Sitarek","orcid":"0000-0001-5495-3550","position":7,"is_corresponding":false},{"id":659605,"name":"Janusz Szemraj","orcid":"0000-0001-6052-3557","position":8,"is_corresponding":false},{"id":1763534,"name":"Tomasz Skorski","orcid":null,"position":9,"is_corresponding":false},{"id":711071,"name":"Tomasz Śliwiński","orcid":"0000-0001-8385-7744","position":10,"is_corresponding":false},{"id":1763524,"name":"Gabriela Barszczewska-Pietraszek","orcid":"0000-0001-7191-3905","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Polθ Inhibitor (ART558) Demonstrates a Synthetic Lethal Effect with PARP and RAD52 Inhibitors in Glioblastoma Cells","abstract":"<jats:p>DNA repair proteins became the popular targets in research on cancer treatment. In our studies we hypothesized that inhibition of DNA polymerase theta (Polθ) and its combination with Poly (ADP-ribose) polymerase 1 (PARP1) or RAD52 inhibition and the alkylating drug temozolomide (TMZ) has an anticancer effect on glioblastoma cells (GBM21), whereas it has a low impact on normal human astrocytes (NHA). The effect of the compounds was assessed by analysis of cell viability, apoptosis, proliferation, DNA damage and cell cycle distribution, as well as gene expression. The main results show that Polθ inhibition causes a significant decrease in glioblastoma cell viability. It induces apoptosis, which is accompanied by a reduction in cell proliferation and DNA damage. Moreover, the effect was stronger when dual inhibition of Polθ with PARP1 or RAD52 was applied, and it is further enhanced by addition of TMZ. The impact on normal cells is much lower, especially when considering cell viability and DNA damage. In conclusion, we would like to highlight that Polθ inhibition used in combination with PARP1 or RAD52 inhibition has great potential to kill glioblastoma cells, and shows a synthetic lethal effect, while sparing normal astrocytes.</jats:p>","is_dataset_classified":null,"base_score":2.302585092994046,"endowment":2.302585092994046,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"39273083","pmcid":"PMC11395082","openalex_id":"https://openalex.org/W4401869830","authors":[],"funders":[{"funder_name":"the Polish National Science Center","grant_id":"UMO-2020/37/B/NZ7/00422","title":null},{"funder_name":"the Polish National Science Center","grant_id":"CA244179","title":null},{"funder_name":"the Polish National Science Center","grant_id":"CA247707","title":null},{"funder_name":"the Polish National Science Center","grant_id":"CA186238","title":null},{"funder_name":"the Polish National Science Center","grant_id":"CA244044","title":null},{"funder_name":"the Polish National Science Center","grant_id":"CA237286","title":null},{"funder_name":"NIH/NCI","grant_id":"1R01 CA244179, CA247707, CA186238, CA244044, and CA2372861","title":null},{"funder_name":"NCI NIH HHS","grant_id":"R01 CA244044","title":null},{"funder_name":"NCI NIH HHS","grant_id":"R01 CA244179","title":null},{"funder_name":"NCI NIH HHS","grant_id":"R01 CA247707","title":null},{"funder_name":"NCI NIH HHS","grant_id":"R01 CA186238","title":null},{"funder_name":"NCI NIH HHS","grant_id":"R01 CA237286","title":null},{"funder_name":"National Institutes of Health","grant_id":"1R01CA244044-01A1","title":"Oncogenic tyrosine kinases inhibitors abrogate DNA repair and sensitive leukemias to PARP inhibitors"},{"funder_name":"National Institutes of Health","grant_id":"5R01CA247707-02","title":"MPN-inducing mutations as biomarkers of synthetic lethality"},{"funder_name":"National Institutes of Health","grant_id":"2R01CA186238-06","title":"Targeting DNA repair to eradicate TKi-refractory/resistant CML and Ph+ALL"},{"funder_name":"National Institutes of Health","grant_id":"5R01CA244179-05","title":"PolQ as a novel therapeutic target in AML"},{"funder_name":"National Institutes of Health","grant_id":"1R01CA237286-01A1","title":"AML mutation-guided drugging of DNA repair"}],"total_grants":17,"fwci":1.6159,"citation_percentile":0.86262086,"influential_citations":0,"citation_trend":[{"year":2025,"count":4},{"year":2026,"count":5}],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://www.mdpi.com/1422-0067/25/17/9134/pdf?version=1724376020","host_type":"journal"},{"url":"https://www.mdpi.com/1422-0067/25/17/9134/pdf?version=1724376020","host_type":"publisher"},{"url":"https://www.mdpi.com/1422-0067/25/17/9134/pdf","host_type":"publisher"},{"url":"https://doi.org/10.3390/ijms25179134","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/39273083","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/11395082","host_type":"repository"},{"url":"https://dx.doi.org/10.3390/ijms25179134","host_type":"repository"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11395082/pdf/ijms-25-09134.pdf","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC11395082","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC11395082?pdf=render","host_type":"Europe_PMC"},{"url":"http://dx.doi.org/10.3390/ijms25179134","host_type":""}],"fields_of_study":["PARP inhibition in cancer therapy","DNA Repair Mechanisms","Cancer therapeutics and mechanisms","0301 basic medicine","03 medical and health sciences","0303 health sciences","Humans","Glioblastoma","Rad52 DNA Repair and Recombination Protein","Poly(ADP-ribose) Polymerase Inhibitors","Cell Line, Tumor","Temozolomide","Poly (ADP-Ribose) Polymerase-1","Cell Survival","Cell Proliferation","DNA Polymerase theta","Apoptosis","DNA Damage","DNA-Directed DNA Polymerase","Synthetic Lethal Mutations","Astrocytes"],"mesh_terms":["Poly(ADP-ribose) Polymerase Inhibitors","Poly (ADP-Ribose) Polymerase-1","Synthetic Lethal Mutations","Temozolomide","DNA Polymerase theta","Astrocytes","Cell Survival","DNA Damage","DNA-Directed DNA Polymerase","Glioblastoma","Humans","Apoptosis","Cell Line, Tumor","Cell Proliferation","Rad52 DNA Repair and Recombination Protein"],"keywords":["Poly ADP ribose polymerase","PARP1","DNA damage","Viability assay","DNA repair","RAD52","Temozolomide","Cell cycle","Apoptosis","Biology","Synthetic lethality","Molecular biology","Cancer cell","Cancer research","Polymerase","Chemistry","DNA","RAD51","Cancer","Biochemistry","Genetics","Glioblastoma","Personalized Therapy","Parp1 Inhibitors","Polθ","Cell Survival","Poly (ADP-Ribose) Polymerase-1","DNA-Directed DNA Polymerase","Poly(ADP-ribose) Polymerase Inhibitors","Article","Cell Line, Tumor","Humans","Cell Proliferation","Rad52 DNA Repair and Recombination Protein","Astrocytes","Synthetic Lethal Mutations","DNA Polymerase theta"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"nct"},{"name":"doi"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-16T19:04:35.750987Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}